CA2407352A1 - Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire - Google Patents

Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire Download PDF

Info

Publication number
CA2407352A1
CA2407352A1 CA002407352A CA2407352A CA2407352A1 CA 2407352 A1 CA2407352 A1 CA 2407352A1 CA 002407352 A CA002407352 A CA 002407352A CA 2407352 A CA2407352 A CA 2407352A CA 2407352 A1 CA2407352 A1 CA 2407352A1
Authority
CA
Canada
Prior art keywords
seq
group
nos
further provides
invention further
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002407352A
Other languages
English (en)
Inventor
Yasir A. W. Skeiky
David H. Persing
Jennifer L. Mitcham
Siqing Steven Wang
Ajay Bhatia
Jean-Francois Maisonneuve
Yanni Zhang
Shyian Jen
Darrick Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2407352A1 publication Critical patent/CA2407352A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne les compositions et les procédés pour la thérapie et le diagnostic de l'acné vulgaire et d'autres états apparentés. Les compositions peuvent comprendre une ou plusieurs protéines de Propionibacterium acnes, des fractions immunogènes de celles-ci, ou des polynucléotides qui codent de telles fractions. Selon une variante, une composition thérapeutique peut comprendre un anticorps qui fixe une protéine de Propionibacterium acnes, une cellule présentant un antigène qui exprime une protéine de Propionibacterium acnes, ou une cellule T qui agit spécifiquement sur les cellules exprimant une telle protéine. De telles compositions peuvent être utilisées, par exemple, pour la prévention et/ou le traitement de l'acné.
CA002407352A 2000-04-21 2001-04-20 Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire Abandoned CA2407352A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US19904700P 2000-04-21 2000-04-21
US60/199,047 2000-04-21
US20884100P 2000-06-02 2000-06-02
US60/208,841 2000-06-02
US21674700P 2000-07-07 2000-07-07
US60/216,747 2000-07-07
PCT/US2001/012865 WO2001081581A2 (fr) 2000-04-21 2001-04-20 Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire

Publications (1)

Publication Number Publication Date
CA2407352A1 true CA2407352A1 (fr) 2001-11-01

Family

ID=27393973

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002407352A Abandoned CA2407352A1 (fr) 2000-04-21 2001-04-20 Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire

Country Status (5)

Country Link
EP (1) EP1278854A2 (fr)
JP (1) JP2004520803A (fr)
AU (1) AU2001255524A1 (fr)
CA (1) CA2407352A1 (fr)
WO (1) WO2001081581A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784830B2 (en) 2010-05-27 2014-07-22 Kenichiro Hasumi Antigen peptide and use thereof

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1947187T5 (da) 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid ekspression af neisserial-proteiner
US20020086837A1 (en) * 2000-12-21 2002-07-04 Jack Gauldie Acne vaccine
US20040175763A1 (en) * 2001-04-24 2004-09-09 Hiroshi Saito Crohn's disease antibody-binding peptide and method of examining crohn's disease
US20030157522A1 (en) * 2001-11-09 2003-08-21 Alain Boudreault Methods and reagents for peptide-BIR interaction screens
WO2003059943A2 (fr) * 2002-01-18 2003-07-24 Karo Bio Ab Peptides specifiques a la conformation, de liaison de la proteine kinase, procedes et produits associes
JP4489582B2 (ja) * 2002-05-28 2010-06-23 オムリクス・バイオフアーマシユーチカルズ・インコーポレーテツド 抗イディオタイプ抗体を得る方法
AU2003273540A1 (en) * 2002-05-31 2003-12-19 Cognosci, Inc. Assays for measuring matrix metalloproteinase activities
DE10232776A1 (de) * 2002-07-18 2004-04-08 Henkel Kgaa Oligonukleotide zum Nachweis von Mikroorganismen
EP1576004A2 (fr) * 2002-12-23 2005-09-21 VIB vzw Proteine immunomodulatrice derivee des trypanosomes et ses utilisations
TWI262192B (en) * 2003-07-01 2006-09-21 Univ Nat Taiwan Labeling peptide for nasopharyngeal carcinoma (NPC) cells
US7723474B2 (en) * 2003-10-21 2010-05-25 The Regents Of The University Of California Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
JPWO2005047313A1 (ja) * 2003-11-14 2007-11-29 株式会社ペプタイドドア ＬｉｐｉｄＡ及びＬＰＳに結合性を有するペプチド又はタンパク質並びに該ペプチド又はタンパク質をコードするＤＮＡ、該ペプチド又はタンパク質を用いたＬＰＳ吸着体あるいはＬＰＳ毒性中和剤
CA2559390A1 (fr) * 2004-03-15 2005-09-22 Tissugen Pty Ltd Etiologie infectieuse de maladie prostatique et procede d'identification d'agents etiologiques
AU2005221729B2 (en) * 2004-03-15 2009-09-24 Tissugen Pty Ltd Infectious aetiology of prostatic disease and methods to identify causative agents
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
ES2340767T5 (es) * 2004-07-01 2013-11-13 Biomay Ag Alérgenos de ácaros del polvo doméstico
US7501486B2 (en) 2004-09-07 2009-03-10 Burnham Institute For Medical Research Peptides that selectively home to heart vasculature and related conjugates and methods
ATE538806T1 (de) * 2004-09-07 2012-01-15 Burnham Inst Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
CA2596079A1 (fr) * 2005-01-31 2006-08-10 Vaxinnate Corporation Nouveaux ligands de polypeptides destines a un recepteur de type toll 2 (tlr2)
DK1863834T3 (da) * 2005-03-22 2010-11-01 Novozymes As Polypeptider og nukleinsyrer, der koder disse
CA2614800C (fr) * 2005-07-12 2018-10-30 Micreos B.V. Bacteriophage specialement concu pour la lyse de la bacterie propionibacterium acnes et son utilisation
US7592009B2 (en) * 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
EP1932852B1 (fr) * 2006-12-15 2010-02-24 Giuseppe Campiani Peptides liées au taxane originales et utilisations de celles-ci
US20090269764A1 (en) * 2008-02-19 2009-10-29 Gen-Probe Incorporated Compositions and methods for detection of propionibacterium acnes nucleic acid
WO2009120993A2 (fr) * 2008-03-28 2009-10-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Analogues synthétiques du domaine juxtamembranaire de l'igf1r et leurs utilisations
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
EP2376534A4 (fr) * 2008-12-05 2012-05-30 Abraxis Bioscience Llc Scfc de liaison à sparc
WO2010065735A2 (fr) * 2008-12-05 2010-06-10 The Regents Of The University Of California Procédés et compositions pour traiter p. acnes
FR2945125B1 (fr) * 2009-05-04 2013-07-19 Ingen Biosciences Methode de diagnostic des infections a propionibacterium acnes
EP2248533B1 (fr) * 2009-05-05 2013-11-06 Universitätsklinikum Freiburg Polypeptide dérivé de l'antérocoque et son utilisation pour la vaccination
FR2959229B1 (fr) * 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
US8481688B2 (en) * 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
US20150086581A1 (en) 2012-03-17 2015-03-26 The Regents Of The University Of California Fast Diagnosis and Personalized Treatment for Acne
CA2904960A1 (fr) * 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Proteines contenant des repetitions d'acides carboxyliques diamines associees a la sla
WO2015138494A1 (fr) * 2014-03-10 2015-09-17 Georges Belfort Peptides anti-microbiens et procédé de conception de nouveaux peptides anti-microbiens
CN118979001A (zh) 2014-06-17 2024-11-19 皇冠实验室有限公司 经遗传修饰的细菌和用于细菌的遗传修饰的方法
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
IL314171A (en) 2015-09-28 2024-09-01 Univ Florida Methods and compositions for antibody-evading virus vectors
EP3416667A4 (fr) * 2016-02-17 2020-02-26 Pepticom Ltd Agonistes et antagonistes peptidiques de l'activation de tlr4
WO2017147507A1 (fr) 2016-02-24 2017-08-31 Xycrobe Therapeutics, Inc. Formulation probiotique à usage cutané
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
JP2019514885A (ja) 2016-04-21 2019-06-06 ネイキッド バイオーム，インク． 皮膚障害の処置のための組成物および方法
CN106167820A (zh) * 2016-05-19 2016-11-30 胤安国际（辽宁）基因科技股份有限公司 鉴定或辅助鉴定痤疮丙酸杆菌的专用引物及其应用
CA3060250A1 (fr) 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regulation de la traduction de la proteine ran par les voies pkr et eif2a-p
US12454549B2 (en) 2017-06-19 2025-10-28 Jenius Pharma, Llc Treatments for diseases and disorders that involve oxidative stress
EP3642219A4 (fr) * 2017-06-19 2021-06-09 Allegro Pharmaceuticals, LLC Compositions peptidiques et procédés associés
US12504380B2 (en) 2017-09-25 2025-12-23 University Of Florida Research Foundation, Incorporated Immunoassays for detection of ran proteins
JP7350337B2 (ja) 2017-09-26 2023-09-26 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
JP7406677B2 (ja) 2018-04-03 2023-12-28 ギンコ バイオワークス インコーポレイテッド 抗体を回避するウイルスベクター
WO2019195444A1 (fr) 2018-04-03 2019-10-10 Stridebio, Inc. Vecteurs viraux évitant les anticorps
WO2019195423A1 (fr) 2018-04-03 2019-10-10 Stridebio, Inc. Vecteurs de virus permettant de cibler des tissus ophtalmiques
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
US20220009959A1 (en) * 2018-11-26 2022-01-13 North Carolina State University Peptide ligands for capture of host cell proteins
CN118307629A (zh) * 2018-12-26 2024-07-09 思亲美有限公司 乙酰胆碱受体抑制肽及其用途
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
WO2021055880A1 (fr) 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Détection d'anticorps contre des protéines ran à partir de lysats sériques et tissulaires
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
KR20220083708A (ko) 2019-10-17 2022-06-20 스트라이드바이오 인코포레이티드 Aav 전달 카세트
JP7684971B2 (ja) * 2019-12-20 2025-05-28 ピーワイシー セラピューティクス リミテッド 新規の細胞内送達方法
CN115996754A (zh) * 2020-02-21 2023-04-21 免疫之源生物技术有限公司 痤疮丙酸杆菌的预防性和治疗性免疫治疗
EP4149511B1 (fr) 2020-05-15 2026-03-25 The University Of Southern California Peptides dérivés de mitochondries et leurs analogues destinés à être utilisés en tant que thérapie pour des maladies liées à l'âge y compris le cancer
BR112022026237A2 (pt) 2020-06-23 2023-01-17 Crown Laboratories Inc Formulações probióticas para a pele
MX2023002016A (es) 2020-08-19 2023-06-26 Sarepta Therapeutics Inc Vectores de virus adenoasociados para el tratamiento del sindrome de rett.
KR20230083100A (ko) * 2021-12-02 2023-06-09 삼성전자주식회사 폴리펩티드, 이를 포함하는 포토레지스트 조성물 및 이를 이용한 패턴 형성 방법
JP2026502948A (ja) * 2022-12-30 2026-01-27 シーダーズ－サイナイ メディカル センター 尋常性ざ瘡の予防および処置のための、ｃ．アクネスヒアルロニダーゼを標的とするワクチン
WO2024231727A1 (fr) 2023-05-05 2024-11-14 Sanofi Compositions destinées à être utilisées dans le traitement de l'acné
EP4516805A1 (fr) * 2023-09-04 2025-03-05 Medizinische Hochschule Hannover Vecteur viral pour transfection de fibroblastes

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784830B2 (en) 2010-05-27 2014-07-22 Kenichiro Hasumi Antigen peptide and use thereof
US9895432B2 (en) 2010-05-27 2018-02-20 Kenichiro Hasumi Compositions, methods and therapies for administering antigen peptide
US10426825B2 (en) 2010-05-27 2019-10-01 Kenichiro Hasumi Compositions, methods and therapies for administering antigen peptide
US11020468B2 (en) 2010-05-27 2021-06-01 Kenichiro Hasumi Compositions, methods and therapies for administering antigen peptide

Also Published As

Publication number Publication date
JP2004520803A (ja) 2004-07-15
EP1278854A2 (fr) 2003-01-29
WO2001081581A3 (fr) 2002-03-14
AU2001255524A1 (en) 2001-11-07
WO2001081581A9 (fr) 2003-01-03
WO2001081581A2 (fr) 2001-11-01

Similar Documents

Publication Publication Date Title
US6630574B1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
US7384638B2 (en) Compounds and methods for treatment and diagnosis of Chlamydial infection
WO2001081581A9 (fr) Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire
WO2003033515A1 (fr) Compositions et methodes pour le traitement et le diagnostic de l'acne vulgaire
JP5053497B2 (ja) 乳癌の治療および診断のための組成物および方法
WO2001040269A2 (fr) Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
US20160362481A1 (en) Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
AU2001273128C1 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6844325B2 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
AU2001273128A1 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2000078960A9 (fr) Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
US20020022591A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
US20050130132A1 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2001070976A2 (fr) Compositions et procedes de therapie et de diagnostic du cancer des ovaires et de l'endometre
WO2001073031A2 (fr) Compositions et methodes destinees au traitement et au diagnostic du cancer de l'ovaire
WO2002002623A2 (fr) Compositions et methodes de diagnostic et de traitement du cancer des poumons
US6686447B1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003020108A2 (fr) Compositions et procedes destines a diagnostiquer et a traiter une infection par le virus de l'herpes simplex
US6914132B1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002012332A2 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du colon
WO2001090154A2 (fr) Compositions et procedes therapeutiques et diagnostiques du cancer ovarien
US20020111308A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
US20030008299A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
US20020137911A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002012329A2 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer de la tete et du cou

Legal Events

Date Code Title Description
FZDE Discontinued